Faculty Opinions recommendation of The cost-effectiveness of community-based screening for oral cancer in high-risk males in the United States: a Markov decision analysis approach.

2011 ◽  
Author(s):  
Michael G Moore ◽  
Michael Harris
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
High Risk ◽  
Oral Cancer ◽  
Decision Analysis ◽  
The United States ◽  
Analysis Approach ◽  
Community Based ◽  
Markov Decision ◽  
The Cost

Cost-Effectiveness of a Targeted Disinfection Program in Household Kitchens To Prevent Foodborne Illnesses in the United States, Canada, and the United Kingdom

2003 ◽  
Vol 66 (11) ◽  
pp. 2103-2115 ◽  
Author(s):  
STEVEN B. DUFF ◽  
ELIZABETH A. SCOTT ◽  
MICHAEL S. MAFILIOS ◽  
EWEN C. TODD ◽  
LEONARD R. KRILOV ◽  
...  
Keyword(s):  
United States ◽  
United Kingdom ◽  
Cost Effectiveness ◽  
High Risk ◽  
The United States ◽  
Foodborne Illnesses ◽  
Cost Effectiveness Ratio ◽  
The United Kingdom ◽  
The Cost

Foodborne illnesses impose a substantial economic and quality-of-life burden on society by way of acute morbidity and chronic sequelae. We developed an economic model to evaluate the potential cost-effectiveness of a disinfection program that targets high-risk food preparation activities in household kitchens. For the United States, Canada, and the United Kingdom, we used published literature and expert opinion to estimate the cost of the program (excluding the educational component); the number of cases of Salmonella, Campylobacter, and Escherichia coli O157:H7 infections prevented; and the economic and quality-of-life outcomes. In our primary analysis, the model estimated that approximately 80,000 infections could be prevented annually in U.S. households, resulting in $138 million in direct medical cost savings (e.g., physician office visits and hospitalizations avoided), 15,845 quality-adjusted life-years (QALYs) gained, $788 million in program costs, and a favorable cost-effectiveness ratio of $41,021/QALY gained. Results were similar for households in Canada and the United Kingdom (Can $21,950/QALY gained and £86,341/QALY gained, respectively). When we evaluated implementing the program only in U.S. households with high-risk members (those less than 5 years of age, greater than 65 years of age, or immunocompromised), the cost-effectiveness ratio was more favorable ($10,163/QALY gained). Results were similar for high-risk households in Canada and the United Kingdom (Can$1,915/QALY gained and £28,158/QALY gained, respectively). Implementing a targeted disinfection program in household kitchens in the United States, Canada, and the United Kingdom appears to be a cost-effective strategy, falling within the range generally considered to warrant adoption and diffusion (<$100,000/QALY gained).

Estimating the Cost-Effectiveness of OnabotulinumtoxinA for Neurogenic Detrusor Overactivity in the United States

2013 ◽  
Vol 35 (4) ◽  
pp. 414-424 ◽  
Author(s):  
Josh J. Carlson ◽  
Ryan N. Hansen ◽  
Roger R. Dmochowski ◽  
Denise R. Globe ◽  
Danielle C. Colayco ◽  
...  
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Detrusor Overactivity ◽  
The United States ◽  
Neurogenic Detrusor Overactivity ◽  
The Cost

scholarly journals Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States

2019 ◽  
Vol 22 (10) ◽  
pp. 981-993 ◽  
Author(s):  
Arielle G. Bensimon ◽  
Zheng-Yi Zhou ◽  
Madeline Jenkins ◽  
Yan Song ◽  
Wei Gao ◽  
...  
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
High Risk ◽  
Adjuvant Treatment ◽  
The United States ◽  
Stage Iii ◽  
Stage Iii Melanoma

scholarly journals The Cost-Effectiveness of Epilepsy Surgery and Surgical Evaluation in the United States

Neurosurgery ◽  
2019 ◽  
Vol 66 (Supplement_1) ◽  
Author(s):  
Shehryar R Sheikh ◽  
Michael P Steinmetz ◽  
Michael W Kattan ◽  
Mendel Singer ◽  
Belinda Udeh ◽  
...  
Keyword(s):  
United States ◽  
Monte Carlo ◽  
Cost Effectiveness ◽  
Epilepsy Surgery ◽  
Medical Management ◽  
Cost Effective ◽  
The United States ◽  
Effective Strategies ◽  
Surgical Evaluation ◽  
The Cost

Abstract INTRODUCTION Surgery is an effective treatment for many pharmacoresistant temporal lobe epilepsy patients, but incurs considerable cost. It is unknown whether surgery and surgical evaluation are cost-effective strategies in the United States. We aim to evaluate whether 1) surgery is cost-effective for patients who have been deemed surgical candidates when compared to continued medical management, 2) surgical evaluation is cost-effective for patients who have drug-resistant temporal epilepsy and may or may not ultimately be deemed surgical candidates METHODS We use a Monte Carlo simulation method to assess the cost-effectiveness of surgery and surgical evaluation over a lifetime horizon. Patients transition between two health states (‘seizure free’ and ‘having seizures’) as part of a Markov process, based on literature estimates. We adopt both healthcare and societal perspectives, including direct healthcare costs and indirect costs such as lost earnings by patients and care providers. We estimate variability of model predictions using probabilistic and deterministic sensitivity analyses. RESULTS 1) Epilepsy surgery is cost effective in surgically eligible patients by virtue of being cost saving and more effective than medical management in the long run, with 95% of 10 000 Monte Carlo simulations favoring surgery. From a societal perspective, surgery becomes cost effective within 3 yr. At 5 yr, surgery has an incremental cost-effectiveness ratio (ICER) of $31,600, which is significantly below the societal willingness-to-pay (∼ $100,000/quality-adjusted life years (QALY)) and comparable to hip/knee arthroplasty. 2) Surgical evaluation is cost-effective in pharmacoresistant patients even if the probability of being deemed a surgical candidate is low (5%-10%). Even if the probability of surgical eligibility is only 10%, surgical referral has an ICER of $96,000/QALY, which is below societal willingness-to-pay. CONCLUSION Epilepsy surgery and surgical evaluation are both cost-effective strategies in the United States. Pharmacoresistant temporal lobe epilepsy patients should be referred for surgical evaluation without hesitation on cost-effectiveness grounds.

Sign in / Sign up

Export Citation Format

Share Document